Oral P2Y12 inhibitors only versus cangrelor in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps
{{output}}
Background: Oral P2Y12 inhibitors (P2Y12i) may have reduced efficacy in critically ill patients undergoing Impella-supported PCI. The intravenous P2Y12i cangrelor offers rapid and reversible platelet inhibition, but its role in t... ...
